

Routine Second Testing in Newborn Screening Project



Harry Hannon, PhD

Jelili Ojodu, MPH

Background

- Only 22.3 % of the newborns in the US receive the possible benefit of a routine second screen.
- Scientific literature indicates that cases of CH and CAH are missed on the initial screen that are detected by a routine second screen.
- To achieve greater uniformity in NBS services, the justification for a routine second screen needs a thorough examination with comprehensive data for an evidence–based decision.

Project Timeline

- Draft Protocol Developed – 2006
- Work Group Meeting – Dec 4-5, 2006
 - 41 participants/ 14 States represented, HRSA, CDC, NNSGRC, APHL, Parent Advocates, Endocrinologists, SACHDNC, Private Lab
- Unanimous support from States and stakeholders to proceed with project
- Project split into a 5-Year Retrospective Project and a 1-Year Prospective Project by Work Group

Study Hypothesis

“Additional cases of congenital hypothyroidism and congenital adrenal hyperplasia are captured by the practice of a routine second screen algorithm.”

Study Questions to Address

- (Are there biochemical or laboratory-based practices that cause non-detected cases on the first screen)?
- (Is the second screen effective in detecting treatable cases and preventing negative outcomes)?
- (If better analytical and post-analytical steps were taken with first specimen screen, would there be a need for a routine second screen)?
- (Is routine second screen a reasonable cost-effective public policy)?

Study Questions

The questions can best be answered by evaluating and validating laboratory and medical results of cases detected in States that perform both first and second routine screens.

Project Protocol: General Content for Laboratory Data For Each Analyte and Screen

- Age of newborn at specimen collection
- Gestational age
- Birth weight of newborn
- Weight of newborn at specimen collection
- Neonatal intensive care unit (NICU) status
- Sex
- Race/Ethnicity
- Feeding Status
- Transfusion status
- Medication/Drugs
- Valid specimen by lab criteria

- Time: (from collection to lab)
- Filter paper (source and lot)
- Assay method
- Time (from lab receipt to assay)
- Final assay value
- Assay in control at all levels
- Cutoff value
- Cutoff algorithm
- Population median value (including case)

Project Protocol: General Content of Medical Data Form


Congenital Hypothyroidism





- Confirmatory test results
- Hypothyroidism type
- Treatment for hypothyroidism
- Neonatal history
- Family history



Congenital Adrenal Hyperplasia

- Prenatal history
- Sex
- CAH type
- Clinical manifestations when came to medical attention
- Degree of virilization
- Imaging studies
- Genetic studies
- Confirmatory serum tests
- Initial medications
- Family history

States with Routine Second Screening



-  Routine/Required
-  Recommended
-  No Second Screen/Controls
-  No Second Screen/Pending Control



CUTOFF VALUES 2008

States	T4 μg/dL serum	TSH μIU/mL serum	17-OHP ng/mL serum
Alabama	5.1	25.0	25.0
Arizona	6.0	60.0	70.0
Colorado	6.0	20.0	55.0
Delaware	3.5	20.0	35.0
Maryland	6.5	20.0	58.0
Nevada	5.0	35.0	75.0
New Mexico	5.0	35.0	75.0
Oregon	5.0	35.0	75.0
Texas	5.9	20.0	67.0
Utah	4.0	25.0	45.0
Wyoming	6.0	20.0	55.0
Washington	-	45.0	90.0
Massachusetts	5.0	20.0	50.0
Wisconsin	-	37.0	86.0

Status of Routine Second Screen Study 2010

States	IRB Status - Retrospective 5-year (date)	IRB Status – Prospective 1-year
Alabama	Jan 2008	Pending
Arizona	Pending	Pending
Colorado	Declined (11/2009)	Pending
Delaware	Dec 2007	Pending
Maryland	July 2008	Pending
Nevada	Pending	Pending
New Mexico	Pending	Pending
Oregon	March 2009	Pending
Texas	Nov 2008	Pending
Utah	Jan 2008	Pending
Wyoming	Pending	Pending
Washington	Pending	Pending
Massachusetts	Pending	Pending
Wisconsin	March 2010	Pending

States	Number of newborns screened in 2008	Presently covered by IRBs for 5-year study
Alabama	64,830	64,830/yr
Arizona	115,371	
Colorado	72,396	
Delaware	13,040	13,040/yr
Maryland	77,753	77,753/yr
Nevada	18,225	
New Mexico	30,986	
Oregon	50,595	50,595/yr
Texas	424,937	424,937/yr
Utah	58,011	58,011/yr
Wyoming	8,030	
Washington	93,083	
Massachusetts	73,828	
Wisconsin	74,383	74,383/yr


Newborns Covered by the Study (To Date)

- 2008 US Births = 4,505,255
- 2008 Newborns with Second Screen = 1,027,257
 - 22.3% of 2008 Births

IRB Approved to Date


- 2008 Second Screen Newborns for Database = 689,116
 - 15.3% of 2008 Births / 67% of Second Screens
- Second Screen Newborns for 5-Year Study = 3,445,580*

Congenital Hypothyroidism Confirmed Cases 2003 - 2008




Congenital Hypothyroidism Confirmed by Second Screen 2003 - 2008

**white bars = no data reported*




Congenital Adrenal Hyperplasia Confirmed Cases 2003 – 2008

**white bars = no data reported*




Congenital Adrenal Hyperplasia Confirmed by Second Screen 2003 - 2008

**white bars = no data reported*



Congenital Hypothyroidism Primary and Secondary Screen 2003 - 2008



Next Steps

- Complete data collection for all states with IRB's approved
- Seek completion of pending IRBs and gather data into electronic files
- Analyze and interpret the laboratory and medical data – designated work group
- Report back to the participant states and newborn screening community
- Submit data and conclusions for publication – peer-reviewed journal

Questions
